AbCellera Biologics Inc. (ABCL) Earnings Call Transcripts
AbCellera Biologics Inc.'s Latest Earnings Call - June 4, 2026
In the Q2 2026 earnings call, AbCellera Biologics Inc. (ABCL:US) reported a significant focus on advancing its proprietary pipeline, particularly the lead molecule ABCL635, aimed at treating vasomotor symptoms (VMS) associated with menopause. The company highlighted a strong liquidity position of $655 million, sufficient to fund operations for at least the next three years. Management indicated that they are moving into Phase II trials for ABCL635, with positive Phase I results suggesting a favorable safety profile and potential for a blockbuster drug in a market estimated at $6 billion. No revenue or earnings figures were disclosed during the call, and guidance remains unchanged as they continue to focus on clinical advancements.
Reported metrics
| Metric | Value |
|---|---|
| Liquidity | $655 million (inline) |
| Total Addressable Market for ABCL635 | $6 billion (positive) |
| Testosterone Reduction in Phase I | 60% (positive) |
| Phase II Trial Size | 80 patients (inline) |
| Expected Phase II Readout | Q3 2026 (positive) |
| Adverse Events in Phase I | notable headache in 900 mg cohort (neutral) |
Guidance from management
Management maintained guidance and emphasized the focus on advancing their proprietary pipeline, with no specific revenue or earnings guidance provided.
What analysts pressed on
Analysts expressed concerns about the competitive landscape for ABCL635 and the challenges faced by the OX40 program. There is also apprehension regarding the potential side effects and market acceptance of the drug amid existing treatments.
Main topics on the call
- Pipeline Advancement — AbCellera is shifting focus from a partnership model to its proprietary pipeline, with two molecules currently in clinical trials and two more expected to enter the clinic in 2027. CFO Andrew Booth stated, "we have suffi...
- ABCL635 Phase I Results — The Phase I trial for ABCL635 demonstrated a favorable tolerability profile and significant target engagement, with a 60% reduction in testosterone levels at the 600 mg dose. Management expressed confidence in moving to ...
- Market Opportunity — The total addressable market for ABCL635 is estimated at $6 billion, targeting approximately 1.2 million women who cannot use hormone replacement therapy for menopause symptoms. Management noted that existing treatments ...
- Safety Profile of ABCL635 — The company reported no liver signals in the Phase I trial, contrasting with competitors that have required liver monitoring. Booth stated, "we believe that an antibody being not metabolized in the liver would have a cle...
Read the full AbCellera Biologics Inc. transcript (June 4, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About AbCellera Biologics Inc.
AbCellera Biologics Inc. (ABCL) is a publicly listed company in the Life Sciences Tools and Services industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 41 calls on record spanning March 29, 2021 to September 9, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 41 AbCellera Biologics Inc. earnings call transcripts on record, spanning March 29, 2021 to September 9, 2026. Based on this history, AbCellera Biologics Inc. reports quarterly. The most recent call on file is dated September 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ABCL
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Life Sciences Tools and Services
- Calls on record
- 41
- First call
- March 29, 2021
- Most recent
- September 9, 2026
- Reporting cadence
- quarterly